COVID-19: Regular market approval granted for Covishield, Covaxin for use in adult population

Under the conditions, the firms shall submit data of ongoing clinical trials and the vaccines to be supplied for programmatic setting besides recording all vaccinations done within the country on the CoWIN platform, the sources said

Press Trust of India January 27, 2022 15:53:03 IST
COVID-19: Regular market approval granted for Covishield, Covaxin for use in adult population

Representational image. PTI

New Delhi: India's drug regulator on Thursday granted regular market approval for COVID-19 vaccines Covishield and Covaxin for use in the adult population subject to certain conditions, official sources said.

The approval was granted under the New Drugs and Clinical Trials Rules, 2019.

Under the conditions, the firms shall submit data of ongoing clinical trials and the vaccines to be supplied for programmatic setting besides recording all vaccinations done within the country on the CoWIN platform, the sources said.

Adverse event following immunisation will continue to be monitored as part of the conditions.

The Drugs Controller General of India's (DCGI) approval came after the Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) on 19 January recommended granting regular market approval to the Serum Institute of India's (SII's) Covishield and Bharat Biotech's Covaxin for use in adult population subject to certain conditions.

Prakash Kumar Singh, Director, Government and Regulatory Affairs at SII, had submitted an application to the DCGI on October 25 seeking regular market authorisation for Covishield.

The DCGI had sought more data and documents from the Pune-based company following which Singh recently had submitted a response along with more data and information.

"Such a large-scale vaccination with Covishield and containment of COVID-19 infection is in itself a testimony of the safety and efficacy of the vaccine," he had said.

In an application sent to the DCGI, V Krishna Mohan, whole-time director at the Hyderabad-based Bharat Biotech, submitted complete information regarding chemistry, manufacturing and controls, along with the pre-clinical and clinical data while seeking regular market authorisation for Covaxin.

Bharat Biotech International Limited (BBIL) took up the challenge to develop, produce and clinically evaluate a vaccine (Covaxin), from the SARS-CoV-2 strains isolated from COVID-19 patients in India, Mohan had said in the application.

Covaxin and Covishield were granted Emergency Use Authorisation (EUA) on 3 January.

Read all the Latest News, Trending NewsCricket News, Bollywood News,
India News and Entertainment News here. Follow us on Facebook, Twitter and Instagram.

Updated Date:

also read

India logs 2,897 new COVID-19 cases, up 26.61% from yesterday; 54 die in last 24 hours
India

India logs 2,897 new COVID-19 cases, up 26.61% from yesterday; 54 die in last 24 hours

COVID-19 daily positivity rate in India has increased to 0.61 per cent, up from 0.47 per cent reported on Tuesday. The weekly positivity rate now stands at 0.74 per cent

India logs 2,124 new COVID-19 cases in last 24 hours, up 26.8% from yesterday
India

India logs 2,124 new COVID-19 cases in last 24 hours, up 26.8% from yesterday

As many as 17 people died of COVID-19 in the country in the last 24 hours, increasing the total casualties due to the virus to 5,24,507

India logs 2,259 new COVID-19 cases, 20 deaths in last 24 hours
India

India logs 2,259 new COVID-19 cases, 20 deaths in last 24 hours

India now has 15,044 active cases of COVID-19. There was a decrease of 375 cases in the active COVID-19 caseload in a span of 24 hours